Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals
Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a ...
Neumora Therapeutics’ stock craters after trial of major depressive disorder fails to meet main goals
Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a ...
Neumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
bovnews5h
Why Did Neumora Therapeutics Inc (NMRA) Soar? Key Factors Explained
Neumora Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -74.98%. The profit margin, also known as the revenue ratio or gross profit ...
Neumora Therapeutics Target of Unusually High Options Trading (NASDAQ:NMRA)
Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired ...
Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops
Neumora Therapeutics stock collapsed Thursday after its experimental depression treatment failed in the first of three ...
Neumora Therapeutics price target lowered to $7 from $22 at BofA
BofA analyst Geoff Meacham lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares.
Neumora Therapeutics (NASDAQ:NMRA) Downgraded to “Sector Perform” Rating by Royal Bank of Canada
Royal Bank of Canada cut shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from an outperform rating to a sector ...
Buy Rating Maintained for Neumora Therapeutics Due to Promising MDD Trial Results and Strong Financial Position
Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report) and keeping the price ...
Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials
Neumora Therapeutics, Inc. (NASDAQ:NMRA) stock traded lower after the company released data from the Phase 3 KOASTAL-1 Study ...
This Is What Whales Are Betting On Neumora Therapeutics
Whales with a lot of money to spend have taken a noticeably bearish stance on Neumora Therapeutics. If we consider the ...
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an ...